1-氯甲酰氧基金刚烷 | 5854-52-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 中文名称: 1-氯甲酰氧基金刚烷
• 英文名称: 1-adamantyl chloroformate
• 英文别名: tricyclo[3.3.1.1^3,7]dec-1-yl chlorocarbonate；adamantanyl carbonochloridate；Adamantyl chloroformate；1-adamantyl carbonochloridate
• CAS: 5854-52-4
• 化学式: C₁₁H₁₅ClO₂
• 分子量: 214.692
• InChiKey: MYTHPILJALAOHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-氯甲酰氧基金刚烷 以 1,4-二氧六环 、 喹啉 、 二氯甲烷 、 水 、 三乙胺 为溶剂， 反应 31.0h， 生成 N-(1-Adamantyloxycarbonyl)-L-serin
  参考文献：
  名称：

  Effenberger, Franz; Brodt, Werner, Chemische Berichte, 1985, vol. 118, # 2, p. 468 - 482

  摘要：

  DOI：
• 作为产物：
  描述：

  光气 、 1-金刚烷醇 在 吡啶 作用下， 以 甲苯 为溶剂， 反应 5.0h， 以77%的产率得到1-氯甲酰氧基金刚烷
  参考文献：
  名称：

  Synthesis and Application of N,N-Bis-(1-adamantyloxycarbonyl) Amino Acids.

  摘要：

  The preparation of novel bis-(1-adamantyloxycarbonyl) amino acid derivatives has been undertaken and their properties studied. Among them, the p-nitrophenyl esters were subsequently applied to the stepwise synthesis of Leu-enkephalin. In the last coupling step, some hydantoin formation was encountered but it could be nearly completely overcome by working with more concentrated solution. The preparation of a tyrosine derivative presented special problems owing to the existence of the phenolic group in the precursor. The relative stability of 1-adamantyloxycarbonyl as N- and O-protecting groups was also studied.

  DOI：

  10.3891/acta.chem.scand.47-0374

文献信息

• [EN] NOVEL GLUTAMINE ANTAGONISTS AND USES THEREOF<br/>[FR] NOUVEAUX ANTAGONISTES DE LA GLUTAMINE ET LEURS UTILISATIONS
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2019071110A1

  公开（公告）日：2019-04-11

  Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof. Also disclosed are methods of enhancing the effects of an immune checkpoint inhibitor, enabling a subject to respond to an immune checkpoint inhibitor, or enabling the toxicity or the dose or number of treatments with an immune checkpoint inhibitor to be reduced, comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof, and an immune checkpoint inhibitor. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder that is refractory to checkpoint inhibitor therapy, the method comprising administering to a subject in need thereof, and having the refractory disease or disorder, a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof.

  谷氨酰胺拮抗剂及其用于治疗肿瘤、免疫和神经系统疾病的方法已被披露。还披露了治疗肿瘤、免疫、传染性或神经系统疾病或紊乱的方法，该方法包括向需要治疗的受试者施用本公开的谷氨酰胺拮抗剂或其药物组成的治疗有效量。还披露了增强免疫检查点抑制剂效果的方法，使受试者对免疫检查点抑制剂产生反应，或减少免疫检查点抑制剂的毒性或剂量或治疗次数的方法，包括向需要治疗的受试者施用本公开的谷氨酰胺拮抗剂或其药物组成的治疗有效量，以及免疫检查点抑制剂。还披露了治疗对检查点抑制剂疗法无效的肿瘤、免疫、传染性或神经系统疾病或紊乱的方法，该方法包括向需要治疗的受试者施用本公开的谷氨酰胺拮抗剂或其药物组成的治疗有效量。
• Enantioselective Alkylamination of Unactivated Alkenes under Copper Catalysis
  作者：Zibo Bai、Heng Zhang、Hao Wang、Hanrui Yu、Gong Chen、Gang He

  DOI：10.1021/jacs.0c12333

  日期：2021.1.20

  An enantioselective addition reaction of various alkyl groups to unactivated internal alkenes under Cu catalysis has been developed. The reaction uses amide-linked aminoquinoline as the directing group, 4-alkyl Hantzsch esters as the donor of alkyl radicals, and rarely used biaryl diphosphine oxide as a chiral ligand. β-lactams featuring two contiguous stereocenters at Cβ and the β substituent can

  已经开发了在铜催化下各种烷基与未活化的内烯烃的对映选择性加成反应。该反应使用酰胺连接的氨基喹啉作为导向基团，4-烷基汉茨酯作为烷基的供体，很少使用联芳基二氧化膦作为手性配体。β-内酰胺在 Cβ 和 β 取代基上具有两个连续的立体中心，可以以良好的收率和优异的对映选择性获得。机理研究表明，烷基自由基与 CuII 配位烯烃的亲核加成是对映体决定步骤。
• Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and mixed CCK-A/CCK-B antagonists
  作者：P. R. Boden、M. Higginbottom、D. R. Hill、D. C. Horwell、J. Hughes、D. C. Rees、E. Roberts、L. Singh、N. Suman-Chauhan、G. N. Woodruff

  DOI：10.1021/jm00057a005

  日期：1993.3

  The design, synthesis, and structure-activity relationships (SAR) for the development of selective dipeptoid ligands for both of the cholecystokinin (CCK) receptor subtypes CCK-A and CCK-B are described. The SAR developed is used to design a ligand with equal nanomolar binding affinity for both the CCK-A and CCK-B receptors. Example compounds such as [1R-[1 alpha[R*(R*)],2 beta]]-4-[[2-[[3-(1H-indol-3-yl)-

  描述了开发胆囊收缩素（CCK）受体亚型CCK-A和CCK-B的选择性二肽配体的设计，合成和结构活性关系（SAR）。开发的SAR用于设计对CCK-A和CCK-B受体均具有相同纳摩尔结合亲和力的配体。示例化合物，例如[1R- [1 alpha [R *（R *）]，2 beta]]-4-[[2-[[3-（1H-吲哚-3-基）-2-甲基-2- [[[（（2-甲基环己基）氧基]羰基]氨基] -1-氧丙基]-氨基] -1-苯基乙基]氨基] -4-氧代丁酸（24c），（1R-反式）-N-α -甲基-N-[[（（2-甲基环己基）氧基]羰基] -D-色氨酸] -L-3-（苯甲基）-β-丙氨酸（28i）和N- [α-甲基-N-[（三环） [3.3.1.1]癸-2-基氧基）羰基] -D-色氨酸] -L-3-（苯甲基）-β-丙氨酸（30m）是具有CCK-B结合亲和力为IC50 = 3.9的CCK-B选择性化合物，
• Mild Metal‐Free Tandem α‐Alkylation/Cyclization of <i>N</i> ‐Benzyl Carbamates with Simple Olefins
  作者：Heinrich Richter、Roland Fröhlich、Constantin‐Gabriel Daniliuc、Olga García Mancheño

  DOI：10.1002/anie.201202379

  日期：2012.8.20

  Easy does it! The chemoselective oxidative α‐C(sp3)H alkylation/cyclization reaction of N‐benzyl carbamates using simple mono‐, di‐, and trisubstituted olefins provides functionalized N‐heterocycles such as oxazinones (see picture). A TEMPO oxoammonium salt serves as the oxidant, making it possible to carry out the reaction at low temperatures. Neither a metal catalyst nor preactivation in the α‐position

  轻而易举！化学选择性氧化α-C（SP 3） h的烷基化/环化反应Ñ使用简单的单，二，和三取代的烯烃-苄基氨基甲酸酯官能提供N-杂环如oxazinones（见图）。甲TEMPO氧代铵盐用作氧化剂时，使得能够进行低温下的反应。既不需要金属催化剂，也不需要在氮位置的α位进行预活化。
• [EN] DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)<br/>[FR] BÊTA-LACTONES DISUBSTITUÉS EN TANT QU'INHIBITEURS DE L'AMIDASE ACIDE DE N-ACYLÉTHANOLAMINE (NAAA)
  申请人：UNIV CALIFORNIA

  公开号：WO2013078430A1

  公开（公告）日：2013-05-30

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了用于抑制N-酰乙醇胺酸酰胺酶（NAAA）的化合物和药物组合物。考虑到抑制NAAA是一种维持棕榈酰乙醇胺（PEA）和油酰乙醇胺（OEA）水平的方法，这两种物质是NAAA的底物，在特征为PEA和OEA浓度降低的情况下。该发明还提供了治疗炎症性疾病和疼痛以及其他与降低PEA和OEA水平相关的疾病的方法。